While no statistically significant difference between tamoxifen and exemestane users was observed in a cross-sectional study of 178 postmenopausal breast cancer patients who underwent hormonal ...
Hosted on MSN3mon
Menopausal status influences long-term benefit from anti-hormonal treatment, study showsMore information: Annelie Johansson et al, Differential Long-Term Tamoxifen Therapy Benefit by Menopausal Status in Breast Cancer Patients: Secondary Analysis of a Controlled Randomized Clinical ...
Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with ... previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback